TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...
Methotrexate is a generic drug prescribed to treat certain types of cancers, arthritis, and psoriasis in adults and some children. As with other drugs, methotrexate can cause side effects, such as ...
Methotrexate 25mg/mL; soln for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free. Non-metastatic osteosarcoma in patients who have undergone surgical resection or ...
The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 15, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms- METHOTREXATE INJECTION ...
The FDA approved pegloticase (Krystexxa) injection coadministered with methotrexate, Horizon Therapeutics announced Friday. Pegloticase is currently the only FDA-approved medication used to reduce ...
TORONTO--(BUSINESS WIRE)--NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet ® for the ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...
Methotrexate comes as an injection given under your skin or into your muscle. It also comes as a tablet you swallow and an intravenous (IV) infusion (an injection into your vein given over time). But ...
The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis ...
LONG BEACH, Calif. -- Methotrexate, during and after surgery for primary retinal detachment, has produced "amazing" early results in preventing proliferative vitreoretinopathy (PVR), according to ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. WARNING: Important safety information is provided in a boxed warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback